Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years

Exclusion Criteria

• •1. Hypersensitivities, allergies or contraindications to study medications; intolerance of medical tape or sticking plaster.
• •2. Clinical or laboratory signs and symptoms of significant cerebral, cardiovascular, respiratory, renal, hepatobiliary, pancreatic or infectious disease, which in the Investigator's judgment may interfere with the study assessment or completion of the study.
• •3. Patients with a known history or predisposition to cardiac conduction interval abnormalities, including QT Syndrome, or known family history of long QT Syndrome or taking medications that are known to prolong the QT interval.
• •4. Patients scheduled to have routine surgery during the study duration.
• •5. Patients with a life expectancy of \< 6 months.
• •6. Scarring or significant skin disease on both upper arms.
• •7. Female patients who are pregnant or breast-feeding. All post menarche female patients must have a pregnancy test at screening.
• •8. Patients who are known or thought to be sexually active must use effective birth control.\*\*
• •9. Administration of other investigational drugs within 30 days preceding the screening visit, except for anticancer treatments.
• •10. Any conditions associated with non-compliance.
• •* Effective birth control includes absolute abstinence or double barrier birth control methods i.e. condom and one of the following: combined oral contraceptive, diaphragm, depot contraceptive injection.